keyword
MENU ▼
Read by QxMD icon Read
search

Borderline ovarian tumor

keyword
https://www.readbyqxmd.com/read/27900026/clinical-implication-of-tiam1-overexpression-in-the-prognosis-of-patients-with-serous-ovarian-carcinoma
#1
Huiwen Li, Xuelian Cui, Dingbao Chen, Yang Yang, Junjie Piao, Zhenhua Lin, Guanghai Yan, Danhua Shen
T lymphoma invasion and metastasis 1 (Tiam1), a guanine nucleotide exchange factor, was originally identified as an invasion- and metastasis-inducing gene in T lymphoma cells. High expression levels of the human Tiam1 gene have been found in numerous human malignancies, suggesting a potential role as a modifier of tumor initiation and progression. However, little is known about the status of Tiam1 in ovarian carcinoma. The present study aimed to investigate the clinicopathological significance of high Tiam1 expression in serous ovarian carcinoma...
November 2016: Oncology Letters
https://www.readbyqxmd.com/read/27889017/staging-procedures-in-patients-with-mucinous-borderline-tumors-of-the-ovary-do-not-reveal-peritoneal-or-omental-disease
#2
Koen De Decker, Stephanie Speth, Henk G Ter Brugge, Joost Bart, Leon F A G Massuger, Marjolein Kleppe, Loes F S Kooreman, Roy F P M Kruitwagen, Arnold-Jan Kruse
OBJECTIVES: Staging in case of a borderline tumor of the ovary (BOT) is a controversial issue. Upstaging is not uncommon, but this occurs especially with presumed stage I serous borderline tumors. There are only a few documented cases of BOTs of non-serous histology that were not confined to the ovary. The aim of this study was to assess the incidence of non-invasive and invasive implants in the omentum and other (extra)pelvic peritoneal surfaces in patients with a mucinous BOT (mBOT)...
November 23, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27889016/is-it-necessary-to-perform-routine-appendectomy-for-mucinous-ovarian-neoplasms-a-retrospective-study-and-meta-analysis
#3
REVIEW
Aoshuang Cheng, Minghao Li, Margaux J Kanis, Ying Xu, Qing Zhang, Baoxia Cui, Jie Jiang, YouZhong Zhang, Xingsheng Yang, Beihua Kong
OBJECTIVES: To evaluate whether routine appendectomy is necessary in all patients with mucinous borderline ovarian tumor (mBOT) or mucinous ovarian cancer (MOC) who undergo gynecologic surgery. METHODS: The database of Qilu Hospital was searched for women who underwent appendectomy in a primary surgery for an ovarian tumor between June 2005 and June 2015 and whose final diagnosis was mBOT, MOC or primary appendiceal tumor. A retrospective review was performed, as well as a meta-analysis of the literature to further validate the findings...
November 23, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27888800/multipoint-kras-oncogene-mutations-potentially-indicate-mucinous-carcinoma-on-the-entire-spectrum-of-mucinous-ovarian-neoplasms
#4
Yi-Ju Lee, Ming-Yung Lee, Alexandra Ruan, Chi-Kuan Chen, Hao-Ping Liu, Chau-Jong Wang, Wan-Ru Chao, Chih-Ping Han
Kras mutation is a common phenomenon in many human neoplasms. We aimed to assess the Kras mutational status along the histological continuum from normal ovaries to the development of benign, borderline and malignant ovarian mucinous neoplasms. We analyzed 41 cases of malignant, 10 cases of borderline, 7 cases of benign mucinous ovarian tumors and 7 cases of normal ovarian tissue. The prevalence of Kras mutations in the normal ovary was 0.00% (n=0/7), while the prevalence in benign, borderline and malignant mucinous neoplasms was 57...
November 18, 2016: Oncotarget
https://www.readbyqxmd.com/read/27887627/epha5-protein-a-potential-marker-for-distinguishing-histological-grade-and-prognosis-in-ovarian-serous-carcinoma
#5
Xiao Chen, Xuan Wang, Xue Wei, Jiandong Wang
BACKGROUND: Ovarian serous carcinoma (OSC) is the most common ovarian epithelial malignancy. Disregulation of Eph/ephrin signaling has been implicated in oncogenesis and tumor progression. EphA5 receptor is one of large families of Eph tyrosine kinase receptor and is documented in the development of nervous system. Till now, there is no published data about the role of EphA5 in ovarian epithelial neoplasmas. METHODS: This study aims to investigate the expression of EphA5 protein in ovarian serous carcinoma, and its relationship to clinical pathological characteristics...
November 25, 2016: Journal of Ovarian Research
https://www.readbyqxmd.com/read/27881340/-expressions-of-ras-and-sos1-in-epithelial-ovarian-cancer-tissues-and-their-clinical-significance
#6
Zheng-Hua Xiao, Hua Linghu, Qian-Fen Liu
OBJECTIVE: To detect the expressions of Ras and Sos1 proteins in human epithelial ovarian cancer (EOC) tissues and explore their correlation with the clinicopathological features of the patients. METHODS: The expressions of Ras and Sos1 proteins were detected immunohistochemically in 62 EOC tissues, 5 borderline ovarian cancer tissues, 15 benign epithelial ovarian neoplasm tissues, and 18 normal ovarian tissues. RESULTS: The EOC tissues showed significantly higher expression levels of both Ras and Sos1 than the other tissues tested (P<0...
November 20, 2016: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/27872782/angiosarcoma-arising-in-ovarian-mucinous-tumor-a-challenge-in-intraoperative-frozen-section-diagnosis
#7
Surapan Khunamornpong, Jongkolnee Settakorn, Kornkanok Sukpan, Tip Pongsuvareeyakul, Sumalee Siriaunkgul
Angiosarcoma of the ovary is rare but represents an aggressive type of malignant ovarian neoplasms. The purpose of this report is to describe the features of angiosarcoma arising in mucinous tumor that was misinterpreted as a benign vascular proliferation during the intraoperative consultation. A 45-year-old woman presented with an abdominal mass for 1 month. Exploratory laparotomy was performed. A 35 cm right ovarian mass submitted for intraoperative consultation was a multicystic mucinous tumor with an 8 cm area of hemorrhagic lesion between cystic locules...
2016: Case Reports in Pathology
https://www.readbyqxmd.com/read/27870789/breaking-borders-a-case-report-of-borderline-ovarian-tumor-in-the-pregnant-patient
#8
Ilana Kafer, Mary Sun, John Pellerito
No abstract text is available yet for this article.
December 2016: Ultrasound Quarterly
https://www.readbyqxmd.com/read/27870706/evaluation-of-a-validated-biomarker-test-in-combination-with-a-symptom-index-to-predict-ovarian-malignancy
#9
Renata R Urban, Alan Smith, Kathy Agnew, Vinicius Bonato, Barbara A Goff
OBJECTIVE: This study aimed to evaluate the predictive ability of a multivariate biomarker test in combination with a symptom index (SI) to identify ovarian cancer in a cohort of women planning to undergo surgery for a pelvic mass. METHODS: This was a prospective study of patients seen at a tertiary care medical center. Following consent, patients completed an SI and preoperative serum was collected for a Food and Drug Administration-cleared multivariate biomarker test [multivariate index assay (MIA)]...
November 17, 2016: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/27852697/chromosomal-instability-in-cell-free-dna-as-a-highly-specific-biomarker-for-detection-of-ovarian-cancer-in-women-with-adnexal-masses
#10
Adriaan Vanderstichele, Pieter Busschaert, Dominiek Smeets, Chiara Landolfo, Els Van Nieuwenhuysen, Karin Leunen, Patrick Neven, Frederic Amant, Sven Mahner, Elena Ioana Braicu, Robert Zeilinger, An Coosemans, Dirk Timmerman, Diether Lambrechts, Ignace Vergote
PURPOSE: Chromosomal instability is a hallmark of ovarian cancer. Here, we explore copy number alteration (CNA) profiling in cell-free DNA as a potential biomarker to detect malignancy in patients presenting with an adnexal mass. EXPERIMENTAL DESIGN: We prospectively enrolled 68 patients with an adnexal mass, of which 57 were diagnosed with invasive or borderline carcinoma and 11 with benign disease. Cell-free DNA was extracted from plasma and analyzed by low-coverage whole-genome sequencing...
November 14, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27852032/complement-component-7-c7-a-potential-tumor-suppressor-is-correlated-with-tumor-progression-and-prognosis
#11
Lisha Ying, Fanrong Zhang, Xiaodan Pan, Kaiyan Chen, Nan Zhang, Jiaoyue Jin, Junzhou Wu, Jianguo Feng, Herbert Yu, Hongchuan Jin, Dan Su
Our previous study found copy number variation of chromosome fragment 5p13.1-13.3 might involve in the progression of ovarian cancer. In the current study, the alteration was validated and complement component 7 (C7), located on 5p13.1, was identified. To further explore the clinical value of C7 in tumors, 156 malignant, 22 borderline, 33 benign and 24 normal ovarian tissues, as well as 173 non-small cell lung cancer (NSCLC) tissues along with corresponding adjacent and normal tissues from the tissue bank of Zhejiang Cancer Hospital were collected...
November 11, 2016: Oncotarget
https://www.readbyqxmd.com/read/27849334/potential-role-of-increasing-number-of-sections-in-frozen-section-diagnosis-of-ovarian-tumors
#12
Ali Ayhan, Ali Ozler, Polat Dursun, A Nihan Haberal
OBJECTIVE: To assess the accuracy of intraoperative frozen section of ovarian tumours at our institution and to identify the possible reasons for misdiagnosis. STUDY DESIGN: Between January 2002 and August 2013, a total of 684 patients were included in the study. Frozen section diagnosis was compared with the final paraffin section diagnosis as the gold standard. The sensitivity, specificity, and positive and negative predictive values of frozen-section diagnosis were calculated for benign, borderline and malignant tumours...
November 2016: Journal of Experimental Therapeutics & Oncology
https://www.readbyqxmd.com/read/27836204/a-nationwide-study-of-ovarian-serous-borderline-tumors-in-denmark-1978-2002-risk-of-recurrence-and-development-of-ovarian-serous-carcinoma
#13
Charlotte Gerd Hannibal, Russell Vang, Jette Junge, Kirsten Frederiksen, Robert J Kurman, Susanne K Kjaer
OBJECTIVE: Absolute risk and risk factors for recurrence and ovarian serous carcinoma following ovarian serous borderline tumors (SBTs) is not well-established. METHODS: We included all women with SBTs in Denmark, 1978-2002. Diagnoses were confirmed by centralized pathology review and classified as atypical proliferative serous tumor (APST) or noninvasive low-grade serous carcinoma (LGSC). Implants were classified as noninvasive or invasive. Medical records were collected and reviewed, and follow-up was obtained...
November 8, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27833989/borderline-brenner-tumors-associated-with-ovarian-cyst-case-presentation
#14
Dinu Florin Albu, Cristina CrenguŢa Albu, Alexandru Marian Gogănău, Ştefan Dimitrie Albu, LaurenŢiu Mogoantă, Antoine Edu, Damian DiŢescu, Constantin Cristian Văduva
Borderline Brenner tumors represent quite a rare entity of ovarian tumors (about 2%) that develop from the surface ovarian epithelium. They are formed from papillary structures made of fibrovascular conjunctive axes covered by a transition epithelium, similar to the urinary bladder epithelium. According to the WHO classification, Brenner tumors present the following forms: benign, borderline and malignant. The benign ones are the most frequent, representing about 95%, the borderline represent about 5%, and the malignant ones less than 1%...
2016: Romanian Journal of Morphology and Embryology, Revue Roumaine de Morphologie et Embryologie
https://www.readbyqxmd.com/read/27831834/role-of-imaging-in-fertility-sparing-treatment-of-gynecologic-malignancies
#15
Andrea G Rockall, Mahrukh Qureshi, Ioanna Papadopoulou, Srdjan Saso, Nicholas Butterfield, Isabelle Thomassin-Naggara, Alan Farthing, J Richard Smith, Nishat Bharwani
Treatments for gynecologic cancer usually result in loss of fertility due to surgery or radical radiation therapy in the pelvis. In countries with an established screening program for cervical cancer, the majority of gynecologic malignancies occur in postmenopausal women. However, a substantial number of affected women are of childbearing age and have not completed their families. In these younger women, consideration of fertility preservation may be important. This article describes the fertility-sparing treatment options that are currently available and outlines the role of imaging in the selection of eligible patients on the basis of a review of the literature...
November 2016: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/27823775/similar-expression-pattern-of-nherf1-and-ezrin-in-papillary-but-not-in-solid-areas-of-human-serous-ovarian-carcinomas
#16
Brenda Demacopulo, Baltazar Eduardo Lema, Rómulo Luis Cabrini, Erica Lorena Kreimann
NHERF1 is an adaptor protein expressed in the apical membrane of polarized epithelia, which interacts with the EZRIN-Radixin-Moesin (ERM) family of proteins connecting signaling pathways to the cell cytoskeleton. NHERF1 and EZRIN cooperate in the maintenance of the apical microvilli in polarized epithelial cells. In several types of cancers, NHERF1 and EZRIN are displaced from the apical compartment to the cytoplasm and nuclei of cancer cells. At the present, the distribution of NHERF1 in ovarian tumors is not well known...
November 4, 2016: Acta Histochemica
https://www.readbyqxmd.com/read/27821183/does-preoperative-neutrophil-to-lymphocyte-or-platelet-to-lymphocyte-ratios-have-a-role-in-predicting-borderline-ovarian-tumors
#17
Ghanim Khatib, Cenk Soysal, Cihan Çetin, Ümran Küçükgöz Güleç, Ahmet Barış Güzel, Nadi Keskin, Mehmet Ali Vardar, Derya Gümürdülü
BACKGROUND: to investigate the value of using preoperative neutrophil to lymphocyte and platelet to lymphocyte levels in the patients of borderline ovarian tumors. METHODS: During the period between January 2002 and December 2015, the pathology reports and archival files of the Gynecologic Oncology Department of Çukurova University Medical Hospital and the Gynecologic Oncology Department of Dumlupınar University, Evliya Çelebi Education and Research Hospital were retrospectively reviewed, and 144 patients of borderline ovarian tumor (as the study group) and 123 patients of serous cystadenoma (as the control group) were determined for eligibility in this study...
November 8, 2016: Journal of Ovarian Research
https://www.readbyqxmd.com/read/27817932/population-based-study-of-survival-for-women-with-serous-cancer-of-the-ovary-fallopian-tube-peritoneum-or-undesignated-origin-on-behalf-of-the-swedish-gynecological-cancer-group-swegcg
#18
Pernilla Dahm-Kähler, Christer Borgfeldt, Erik Holmberg, Christian Staf, Henrik Falconer, Maria Bjurberg, Preben Kjölhede, Per Rosenberg, Karin Stålberg, Thomas Högberg, Elisabeth Åvall-Lundqvist
OBJECTIVE: The aim of the study was to determine survival outcome in patients with serous cancer in the ovary, fallopian tube, peritoneum and of undesignated origin. METHODS: Nation-wide population-based study of women≥18years with histologically verified non-uterine serous cancer, included in the Swedish Quality Registry for primary cancer of the ovary, fallopian tube and peritoneum diagnosed 2009-2013. Relative survival (RS) was estimated using the Ederer II method...
November 3, 2016: Gynecologic Oncology
https://www.readbyqxmd.com/read/27801762/value-of-pathology-review-in-a-population-based-series-of-ovarian-tumors
#19
Colin J R Stewart, Louise M Stewart, C D'Arcy J Holman, Susan Jordan, James Semmens, Katrina Spilsbury, Timothy Threlfall
Ovarian neoplasia comprises a heterogenous group of tumors with distinct clinicopathologic and molecular features and therefore assessment of potential risk factors should be tumor subtype specific. As part of ongoing epidemiological investigations of ovarian neoplasia in Western Australia, we performed an initial review of original pathology reports followed, in selected cases, by reassessment of histology material to optimize accurate diagnosis. Additional immunohistochemistry, often using antibodies unavailable at the time of initial assessment, was also performed as required...
October 31, 2016: International Journal of Gynecological Pathology
https://www.readbyqxmd.com/read/27798689/clinical-significance-of-tissue-factor-pathway-inhibitor-2-a-serum-biomarker-candidate-for-ovarian-clear-cell-carcinoma
#20
Noriaki Arakawa, Hiroshi Kobayashi, Naohiro Yonemoto, Yusuke Masuishi, Yoko Ino, Hiroshi Shigetomi, Naoto Furukawa, Norihisa Ohtake, Yohei Miyagi, Fumiki Hirahara, Hisashi Hirano, Etsuko Miyagi
BACKGROUND: There is currently no reliable serum biomarker for ovarian clear cell carcinoma (CCC), a highly lethal histological subtype of epithelial ovarian cancer (EOC). Previously, using a proteome-based approach, we identified tissue factor pathway inhibitor 2 (TFPI2) as a candidate serum biomarker for CCC. In this study, we sought to evaluate the clinical diagnostic performance of TFPI2 in preoperative prediction of CCC. METHODS: Serum TFPI2 levels were measured in serum samples from a retrospective training set consisting of patients with benign and borderline ovarian tumors, EOC subtypes, and uterine diseases...
2016: PloS One
keyword
keyword
74363
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"